Skip to main content

CA209-9KY: IMRT + nivolumab for recurrent head and neck squamous cell cancer



Nabil F. Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the CA209-9KY trial …

source

Leave a Reply

Your email address will not be published. Required fields are marked *